Sikander Ailawadhi, MD

Articles

Dr. Ailawadhi on the Results of a First-in-Human Study of Lisaftoclax in Hematologic Malignancies

September 20th 2021

Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.

Dr. Ailawadhi on Patient Considerations for BTK Inhibitors in Waldenström Macroglobulinemia

September 3rd 2021

Sikander Ailawadhi, MD, discusses patient considerations for BTK inhibitors in Waldenström macroglobulinemia.

Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL

June 30th 2021

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Safety Profile of Lisaftoclax in CLL

June 25th 2021

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Rationale to Evaluate Lisaftoclax in CLL

June 9th 2021

Sikander Ailawadhi, MD, discusses the rationale to evaluate lisaftoclax in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Efficacy of Lisaftoclax in Hematologic Malignancies

June 7th 2021

Sikander Ailawadhi, MD, discusses the activity of lisaftoclax in patients with hematologic malignancies.

Dr. Ailawadhi on Potential Combination Strategies in Multiple Myeloma

January 26th 2021

Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.

Dr. Ailawadhi on the Emergence of T-Cell Engagers in Multiple Myeloma

January 13th 2021

Sikander Ailawadhi, MD, discusses the emergence of T-cell engagers in multiple myeloma.

Dr. Ailawadhi on the Potential Role of Melflufen in Multiple Myeloma

January 7th 2021

Sikander Ailawadhi, MD, discusses the potential role of melflufen in multiple myeloma.

Dr. Ailawadhi on the Integration of Selinexor in Relapsed/Refractory Multiple Myeloma

January 5th 2021

Sikander Ailawadhi, MD, discusses the integration of selinexor into the treatment landscape of relapsed/refractory multiple myeloma.